Targeting senescent cells alleviates obesity-induced metabolic dysfunction

doi:10.1111/acel.12950

. 2019 Jun;18(3):e12950.

doi: 10.1111/acel.12950. Epub 2019 Mar 25.

Targeting senescent cells alleviates obesity-induced metabolic dysfunction

Allyson K Palmer^{1

2

3}, Ming Xu^{1

4}, Yi Zhu¹, Tamar Pirtskhalava¹, Megan M Weivoda¹, Christine M Hachfeld¹, Larissa G Prata¹, Theo H van Dijk⁵, Esther Verkade⁶, Grace Casaclang-Verzosa¹, Kurt O Johnson¹, Hajrunisa Cubro⁷, Ewald J Doornebal¹, Mikolaj Ogrodnik^{1

8}, Diana Jurk^{1

8}, Michael D Jensen³, Eduardo N Chini^{1

9

10}, Jordan D Miller^{1

9

11}, Aleksey Matveyenko⁹, Michael B Stout^{1

12

13

14}, Marissa J Schafer¹, Thomas A White¹, LaTonya J Hickson^{7

15}, Marco Demaria^{16

17}, Vesna Garovic⁷, Joseph Grande¹⁸, Edgar A Arriaga¹⁹, Folkert Kuipers^{5

6}, Thomas von Zglinicki⁸, Nathan K LeBrasseur^{1

9

20}, Judith Campisi¹⁶, Tamar Tchkonia¹, James L Kirkland^{1

3

9

15}

Affiliations

¹ Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota.
² Medical Scientist Training Program, Mayo Clinic, Rochester, Minnesota.
³ Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
⁴ University of Connecticut Center on Aging, University of Connecticut Health, Farmington, Connecticut.
⁵ Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
⁶ Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
⁷ Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
⁸ Institute for Ageing, Ageing Research Laboratories, Newcastle University, Newcastle upon Tyne, UK.
⁹ Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota.
¹⁰ Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota.
¹¹ Department of Surgery, Mayo Clinic, Rochester, Minnesota.
¹² Department of Nutritional Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
¹³ Reynolds Oklahoma Center on Aging, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
¹⁴ Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
¹⁵ Division of Geriatric Medicine and Gerontology, Mayo Clinic, Rochester, Minnesota.
¹⁶ Buck Institute for Research on Aging, Novato, California.
¹⁷ European Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
¹⁸ Department of Pathology, Mayo Clinic, Rochester, Minnesota.
¹⁹ Department of Chemistry, University of Minnesota, Minneapolis, Minnesota.
²⁰ Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota.

PMID: 30907060
PMCID: PMC6516193
DOI: 10.1111/acel.12950

Targeting senescent cells alleviates obesity-induced metabolic dysfunction

Allyson K Palmer et al. Aging Cell. 2019 Jun.

. 2019 Jun;18(3):e12950.

doi: 10.1111/acel.12950. Epub 2019 Mar 25.

Authors

Affiliations

¹ Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, Minnesota.
² Medical Scientist Training Program, Mayo Clinic, Rochester, Minnesota.
³ Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
⁴ University of Connecticut Center on Aging, University of Connecticut Health, Farmington, Connecticut.
⁵ Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
⁶ Department of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
⁷ Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota.
⁸ Institute for Ageing, Ageing Research Laboratories, Newcastle University, Newcastle upon Tyne, UK.
⁹ Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota.
¹⁰ Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota.
¹¹ Department of Surgery, Mayo Clinic, Rochester, Minnesota.
¹² Department of Nutritional Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
¹³ Reynolds Oklahoma Center on Aging, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
¹⁴ Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
¹⁵ Division of Geriatric Medicine and Gerontology, Mayo Clinic, Rochester, Minnesota.
¹⁶ Buck Institute for Research on Aging, Novato, California.
¹⁷ European Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
¹⁸ Department of Pathology, Mayo Clinic, Rochester, Minnesota.
¹⁹ Department of Chemistry, University of Minnesota, Minneapolis, Minnesota.
²⁰ Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota.

PMID: 30907060
PMCID: PMC6516193
DOI: 10.1111/acel.12950

Abstract

Adipose tissue inflammation and dysfunction are associated with obesity-related insulin resistance and diabetes, but mechanisms underlying this relationship are unclear. Although senescent cells accumulate in adipose tissue of obese humans and rodents, a direct pathogenic role for these cells in the development of diabetes remains to be demonstrated. Here, we show that reducing senescent cell burden in obese mice, either by activating drug-inducible "suicide" genes driven by the p16^Ink4a promoter or by treatment with senolytic agents, alleviates metabolic and adipose tissue dysfunction. These senolytic interventions improved glucose tolerance, enhanced insulin sensitivity, lowered circulating inflammatory mediators, and promoted adipogenesis in obese mice. Elimination of senescent cells also prevented the migration of transplanted monocytes into intra-abdominal adipose tissue and reduced the number of macrophages in this tissue. In addition, microalbuminuria, renal podocyte function, and cardiac diastolic function improved with senolytic therapy. Our results implicate cellular senescence as a causal factor in obesity-related inflammation and metabolic derangements and show that emerging senolytic agents hold promise for treating obesity-related metabolic dysfunction and its complications.

Keywords: adipogenesis; aging; cellular senescence; dasatinib; quercetin; senolytics; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

J.L.K., T.T., T.P., A.K.P., Y.Z., M.X., J.C., and M.D. have a financial interest related to this research. Patents on senolytic drugs are held by Mayo Clinic. This research has been reviewed by the Mayo Clinic and Buck Institute Conflict of Interest Review Boards and was conducted in compliance with Mayo Clinic and Buck Institute Conflict of Interest policies. None of the other authors has a relevant conflict of financial interest.

Figures

**Figure 1**
Removal of obesity‐induced senescent cells from adipose tissue. (a, b) *Renilla* luciferase activity in DIO p16‐3MR mice (a, representative image), quantified in b (n = 6–9 per group). (c) *Renilla* luciferase activity localization in DIO p16‐3MR dissected tissues. (d, e) Senescence‐associated beta‐galactosidase (SA‐β‐gal) activity as whole tissue activity (d; representative image) and % positive cells of total DAPI⁺ cells in p16‐3MR VAT (e; chow n = 3, DIO n = 7–9 per group). (f) Expression of p16‐3MR transgene (eGFP) components (*Renilla* luciferase and mRFP) and p16^Ink4a (chow n = 3, DIO n = 11 per group) in p16‐3MR VAT. (g, h) Senescence‐associated beta‐galactosidase (SA‐β‐gal) activity as whole tissue activity (g; representative image) and % positive cells of total DAPI⁺ cells in p16‐3MR VAT (h; n = 3–4 per group). (i) p16^Ink4a mRNA levels (c; chow n = 8, DIO n = 19–21 per group) in VAT of D + Q‐treated DIO mice. (j) Percent of VAT stromal vascular fraction (SVF) cells highly expressing FLAG (a component of the *p16^Ink4a* promoter‐driven ATTAC fusion protein), CENP‐B, and p21^Cip1 after a single course of D + Q (o, n = 6 per group) in DIO INK‐ATTAC mice. Means ± *SEM* are shown. Box and whisker plot show minimum, mean, maximum, 25th and 75th percentiles. *p < 0.05, **p < 0.005, ***p < 0.0005; one‐way ANOVA with Bonferroni correction or two‐tailed Student's t test when comparing two groups

**Figure 2**
Eliminating senescent cells enhances glucose homeostasis and insulin sensitivity. (a, b) Intraperitoneal glucose tolerance test in DIO p16‐3MR (a; chow n = 4, DIO n = 6–7 per group) and DIO wild‐type mice treated with D + Q (b, chow n = 4, DIO n = 11 per group) following senescent cell clearance. (c) Hemoglobin A1c in DIO p16‐3MR (chow n = 4, DIO n = 15–18 per group) and DIO wild‐type mice treated with D + Q (chow n = 6, DIO n = 11–12 per group). (d, e) ITT following ganciclovir treatment in p16‐3MR mice (d, n = 4 chow, n = 18–19 DIO groups), or D + Q treatment in DIO wild‐type mice (e, chow n = 6, DIO n = 11–12 per group). (f) Fold change in AKT serine‐473 phosphorylation after 5‐min ex vivo 5 nM insulin stimulation in freshly isolated p16‐3MR VAT (n = 3 per group). For each mouse, p‐AKT was normalized to total AKT and expressed as a ratio of p‐AKT in insulin‐exposed tissue to p‐AKT in noninsulin‐exposed tissue. (g) Glucose infusion rate (GIR) during hyperinsulinemic–euglycemic clamp in DIO mice treated with vehicle or D + Q (n = 8 per group). (h) Plasma insulin concentration at baseline and during hyperglycemic clamping (HGC) in DIO mice treated with D + Q (n = 8 per group). (i) Glucose appearance rate (Ra) during basal, hyperglycemic, and hyperinsulinemic–euglycemic clamping in DIO mice treated with D + Q (n = 8 per group). Means ± *SEM* are shown. *p < 0.05, **p < 0.005, ***p < 0.0005; one‐way ANOVA with Bonferroni correction for multiple comparisons. ^# p < 0.05, two‐tailed Student's t test comparing DIO vehicle‐treated group to DIO ganciclovir‐treated, or D + Q‐treated group. Groups of interest were compared at each time point for GTTs and ITTs

**Figure 3**
Adipogenesis is enhanced by senescent cell reduction. (a, b) Plasma activin A in p16‐3MR mice (a; chow n = 3, DIO n = 9–11) and D + Q‐treated DIO mice (b, chow n = 3, DIO n = 11–12). (c, d) Adipogenic gene expression in cells isolated from subcutaneous adipose tissue stromal vascular fraction (SVF) of p16‐3MR (c; n = 5–7 per group) and D + Q‐treated mice (d, n = 3 per group). (e) Representative images of lipid droplet formation during differentiation of adipocyte progenitors isolated from vehicle‐ or ganciclovir‐treated p16‐3MR mice after 5‐day exposure to differentiation medium (scale bars indicate 50 μm). (f) VAT cell size in p16‐3MR mice and D + Q‐treated mice (n = 3–7 per group). (g, h) Subcutaneous:intra‐abdominal adipose ratio in DIO p16‐3MR mice (g, n = 5–6 per group) and D + Q‐treated mice (h, n = 18–21 per group). Means ± *SEM* are shown. *p < 0.05; one‐way ANOVA with Bonferroni correction or two‐tailed Student's t test when comparing two groups

**Figure 4**
Senescent cells promote macrophage infiltration. (a) Correlation of FLAG⁺ cells with F4/80⁺/Cd11b⁺ macrophages in the SVF of DIO INK‐ATTAC VAT as analyzed by CyTOF (n = 30). (b) Plasma cytokines in ganciclovir‐treated DIO p16‐3MR mice (n = 19–22 per group). (c) F4/80 mRNA in VAT of ganciclovir‐treated p16‐3MR DIO mice (chow n = 4, DIO n = 17–22 per group). (d, e) F4/80⁺ crown‐like structures in VAT of ganciclovir‐treated p16‐3MR DIO mice (representative photographs in d, quantified in e; chow n = 4; DIO n = 5–8 per group). (f) THP‐1 cell migration into a Transwell containing either nonirradiated or irradiated (senescent) adipocyte progenitors, with no addition of antibody (control), addition of nonspecific antibody (IgG), or addition of antibodies against MCP‐1, MIP1‐β, or M‐CSF (n = 4 per condition). (g, h) Representative image of luminescence signal in AP20187‐treated INK‐ATTAC;*db/db* mice 24 hr following i.v. injection of 1 × 10⁶ luciferase⁺ monocytes (g), normalized to vehicle‐treated mice and quantified in h (n = 6 per group). (i) Quantification of luminescence in D + Q‐treated *db/db* mice 24 hr following i.v. injection of 1 × 10⁶ luciferase⁺ monocytes isolated from CAG‐luc mice, normalized to vehicle‐treated mice (n = 5 per group). Means ± *SEM* are shown. *p < 0.05, **p < 0.005, ***p < 0.0005; one‐way ANOVA with Bonferroni correction or two‐tailed Student's t test when comparing two groups

**Figure 5**
Complications of diabetes are alleviated by senescent cell clearance. (a–c) Parameters of diastolic function in p16‐3MR *db/db* mice treated with ganciclovir determined by echocardiography–Doppler measurements (n = 5–8 per group): (a) Early diastolic velocity from medial mitral annulus (e′); (b) isovolumic relaxation time (IVRT) c, left ventricular filling pressure (E/e′) (n = 5–8 per group); (d) left ventricular ejection fraction (EF), an indicator of systolic function, in p16‐3MR lean or *db/db* mice treated with ganciclovir (n = 5–8 per group). (e) Number of cells per glomerulus staining positively for Wilms tumor protein in D + Q‐treated DIO mice (WT‐1; e, n = 4 per group). (f) Average number of p16^Ink4a‐positive cells per field in the renal cortex of D + Q‐treated DIO mice (n = 4 per group). (g, h) Urine albumin/creatinine ratio (ACR) in DIO p16‐3MR mice treated with ganciclovir (g, chow n = 4, DIO n = 9–11 per group) or DIO wild‐type mice treated with D + Q (h, n = 6–9 per group). Means ± *SEM* are shown. *p < 0.05, ***p < 0.0005, ****p < 0.0001; one‐way ANOVA with Bonferroni correction or two‐tailed Student's t test when comparing two groups

See this image and copyright information in PMC

Cited by

Cellular senescence in cancer: from mechanisms to detection.
Ou HL, Hoffmann R, González-López C, Doherty GJ, Korkola JE, Muñoz-Espín D. Ou HL, et al. Mol Oncol. 2021 Oct;15(10):2634-2671. doi: 10.1002/1878-0261.12807. Epub 2020 Oct 22. Mol Oncol. 2021. PMID: 32981205 Free PMC article. Review.
Inflammation/bioenergetics-associated neurodegenerative pathologies and concomitant diseases: a role of mitochondria targeted catalase and xanthophylls.
Filippov MA, Tatarnikova OG, Pozdnyakova NV, Vorobyov VV. Filippov MA, et al. Neural Regen Res. 2021 Feb;16(2):223-233. doi: 10.4103/1673-5374.290878. Neural Regen Res. 2021. PMID: 32859768 Free PMC article. Review.
Evaluating causality of cellular senescence in non-alcoholic fatty liver disease.
Meijnikman AS, Herrema H, Scheithauer TPM, Kroon J, Nieuwdorp M, Groen AK. Meijnikman AS, et al. JHEP Rep. 2021 May 1;3(4):100301. doi: 10.1016/j.jhepr.2021.100301. eCollection 2021 Aug. JHEP Rep. 2021. PMID: 34113839 Free PMC article. Review.
Systemic overexpression of C-C motif chemokine ligand 2 promotes metabolic dysregulation and premature death in mice with accelerated aging.
Luciano-Mateo F, Cabré N, Baiges-Gaya G, Fernández-Arroyo S, Hernández-Aguilera A, Elisabet Rodríguez-Tomàs E, Arenas M, Camps J, Menéndez JA, Joven J. Luciano-Mateo F, et al. Aging (Albany NY). 2020 Oct 26;12(20):20001-20023. doi: 10.18632/aging.104154. Epub 2020 Oct 26. Aging (Albany NY). 2020. PMID: 33104522 Free PMC article.
Senolytic Therapy: A Potential Approach for the Elimination of Oncogene-Induced Senescent HPV-Positive Cells.
Saleh T, Khasawneh AI, Himsawi N, Abu-Raideh J, Ejeilat V, Elshazly AM, Gewirtz DA. Saleh T, et al. Int J Mol Sci. 2022 Dec 8;23(24):15512. doi: 10.3390/ijms232415512. Int J Mol Sci. 2022. PMID: 36555154 Free PMC article. Review.

See all "Cited by" articles

References

1. Baker, D. J. , Wijshake, T. , Tchkonia, T. , LeBrasseur, N. K. , Childs, B. G. , van de Sluis, B. , … van Deursen, J. M. (2011). Clearance of p16Ink4a‐positive senescent cells delays ageing‐associated disorders. Nature, 479, 232–236. 10.1038/nature10600 - DOI - PMC - PubMed
1. Caballero, A. E. (2003). Endothelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease. Obesity Research, 11, 1278–1289. 10.1038/oby.2003.174 - DOI - PubMed
1. Chang, J. , Wang, Y. , Shao, L. , Laberge, R.‐M. , Demaria, M. , Campisi, J. , … Zhou, D. (2016). Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature Medicine, 22, 78–83. 10.1038/nm.4010 - DOI - PMC - PubMed
1. Childs, B. G. , Baker, D. J. , Wijshake, T. , Conover, C. A. , Campisi, J. , & van Deursen, J. M. (2016). Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science, 354, 472–477. 10.1126/science.aaf6659 - DOI - PMC - PubMed
1. Christopher, L. J. , Cui, D. , Wu, C. , Luo, R. , Manning, J. A. , Bonacorsi, S. J. , … Iyer, R. A. (2008). Metabolism and disposition of dasatinib after oral administration to humans. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 36, 1357–1364. 10.1124/dmd.107.018267 - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- H1 Connect
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Molecular Biology Databases
- Mouse Genome Informatics (MGI)

[1] Baker, D. J. , Wijshake, T. , Tchkonia, T. , LeBrasseur, N. K. , Childs, B. G. , van de Sluis, B. , … van Deursen, J. M. (2011). Clearance of p16Ink4a‐positive senescent cells delays ageing‐associated disorders. Nature, 479, 232–236. 10.1038/nature10600 - DOI - PMC - PubMed

[2] Baker, D. J. , Wijshake, T. , Tchkonia, T. , LeBrasseur, N. K. , Childs, B. G. , van de Sluis, B. , … van Deursen, J. M. (2011). Clearance of p16Ink4a‐positive senescent cells delays ageing‐associated disorders. Nature, 479, 232–236. 10.1038/nature10600 - DOI - PMC - PubMed

[3] Caballero, A. E. (2003). Endothelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease. Obesity Research, 11, 1278–1289. 10.1038/oby.2003.174 - DOI - PubMed

[4] Caballero, A. E. (2003). Endothelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease. Obesity Research, 11, 1278–1289. 10.1038/oby.2003.174 - DOI - PubMed

[5] Chang, J. , Wang, Y. , Shao, L. , Laberge, R.‐M. , Demaria, M. , Campisi, J. , … Zhou, D. (2016). Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature Medicine, 22, 78–83. 10.1038/nm.4010 - DOI - PMC - PubMed

[6] Chang, J. , Wang, Y. , Shao, L. , Laberge, R.‐M. , Demaria, M. , Campisi, J. , … Zhou, D. (2016). Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nature Medicine, 22, 78–83. 10.1038/nm.4010 - DOI - PMC - PubMed

[7] Childs, B. G. , Baker, D. J. , Wijshake, T. , Conover, C. A. , Campisi, J. , & van Deursen, J. M. (2016). Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science, 354, 472–477. 10.1126/science.aaf6659 - DOI - PMC - PubMed

[8] Childs, B. G. , Baker, D. J. , Wijshake, T. , Conover, C. A. , Campisi, J. , & van Deursen, J. M. (2016). Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science, 354, 472–477. 10.1126/science.aaf6659 - DOI - PMC - PubMed

[9] Christopher, L. J. , Cui, D. , Wu, C. , Luo, R. , Manning, J. A. , Bonacorsi, S. J. , … Iyer, R. A. (2008). Metabolism and disposition of dasatinib after oral administration to humans. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 36, 1357–1364. 10.1124/dmd.107.018267 - DOI - PubMed

[10] Christopher, L. J. , Cui, D. , Wu, C. , Luo, R. , Manning, J. A. , Bonacorsi, S. J. , … Iyer, R. A. (2008). Metabolism and disposition of dasatinib after oral administration to humans. Drug Metabolism and Disposition: the Biological Fate of Chemicals, 36, 1357–1364. 10.1124/dmd.107.018267 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Targeting senescent cells alleviates obesity-induced metabolic dysfunction

Affiliations

Targeting senescent cells alleviates obesity-induced metabolic dysfunction

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases